US FDA advises COVID vaccine makers to develop shots aimed at XBB.1.5 variant
Reuters
Published Jun 16, 2023 04:22PM ET
(Reuters) - The U.S. Food and Drug Administration (FDA) said on Friday it has advised manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target the XBB.1.5 subvariant.
So-called monovalent, or single-target vaccines, would be a change from the most recent bivalent COVID boosters that targeted both the original and Omicron strains of the coronavirus.
The FDA's advice comes a day after its panel of experts unanimously recommended that the updated COVID shots being developed for a fall vaccination campaign target one of the currently dominant XBB coronavirus variants.
COVID vaccine makers Pfizer/BioNTech, Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) are already developing versions of their respective vaccines to target XBB.1.5 and other currently circulating subvariants.
Novavax's XBB.1.5 COVID vaccine candidate is being manufactured at commercial scale, with plans for it to be in the market for the fall campaign, the company said on Friday.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.